

Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messsinger Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Jeffrey T. Helvey* Heidi L. Kraus Edward W. Yee Albert L. Ferro* Donald R. Banowit Peter A. Jackman Molly A. McCall Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Albert J. Fasulo II* Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston' Kimberly N. Reddick Theodore A. Wood Elizabeth J. Haanes Bruce E. Chalker Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn Prengaman Jane Shershenovich' Lawrence J. Carroll' George S. Bardmesser Daniel A. Klein' Rodney G. Maze Jason D. Eisenberg Michael A. Specht' Andrea J. Kamage Tracy L. Muller'

Jon E. Wright*
LuAnne M. Yuricek*

Registered Patent Agents-Karen R. Markowicz Nancy J. Leith Ann E. Summerfield Helene C. Carlson Gaby L. Longsworth Matthew J. Dowd Aaron L. Schwartz Angelique G. Uy Boris A. Matvenko Mary B. Tung Katrina Y. Pei Bryan L. Skelton Robert A. Schwartzman John J. Fiqueroa Timothy A. Doyle Jennifer R. Mahalingappa Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford W. Brian Edge

Senior Counsel
Samuel L. Fox
Kenneth C. Bass III

*Admitted only in Maryland

* Admitted only in Virginia

* Admitted only in Texas

*Practice Limited to

Federal Agencies

December 23, 2002

RECEIVED

WRITER'S DIRECT NUMBER: (202) 371-2606 INTERNET ADDRESS: anns@skgf.com

DEC 2 7 2002

Commissioner for Patents Washington, D.C. 20231

TECH CENTER 1600/2900

Art Unit 1635

Re:

U.S. Utility Patent Application

Appl. No. 09/839,574; Filed: April 23, 2001

For: Compositions and Methods for in vivo Delivery of Polynucleotide-

Based Therapeutics

Inventors:

MANTHORPE et al.

Our Ref:

1530.0180002/EKS/EJH

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Amendment And Reply Under 37 C.F.R. § 1.111, with Exhibits 1-2, as follows:
 - 1) copy of Schmolka, I.R., J. Amer. Oil Chemists' Soc. 54:110-116 (1977) (Exhibit 1);
 - 2) copy of BASF Corp. publication entitled "Nomenclature and PLURONIC® Surfactant Grid" (Exhibit 2);
- 2. Third Supplemental Information Disclosure Statement;
- 3. Form PTO-1449 (2 pages), listing nine (9) documents;
- 4. Copies of nine documents cited on Form PTO-1449 (nos. AO2, AP2, AL3-AP3 AT11 and AR12);
- 5. Petition For Extension of Time Under 37 C.F.R. § 1.136(a)(1);
- 6. Fee Transmittal (PTO/SB/17);
- 7. Credit Card Payment Form; and
- 8. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are

Sterne, Kessler, Goldstein & Fox P.L.L.C.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents December 23, 2002 Page 2

necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Ann E . Summefuld


Ann E. Summerfield

Agent for Applicants

Registration No. 47,982

Enclosures

::ODMA\MHODMA\SKGF_DC1;87025;1 SKGF Rev. 2/15/02 dcw





Application

09/839,574

Number:

Attorney Docket

1530.0180002

Number:

Stylesheet Version: 1.0

Submission Type: Information

Disclosure Statement

Compositions and Methods for in vivo Delivery of Polynucleotide-Based Therapeutics

First Named Inventor: Marston Manthorpe

RECEIVED

DEC 2 7 2002

TECH CENTER 1600/2900

SUBMITTED BY

Name:

Ann E. Summerfield

.... 2. 2

Registration Number:

47,982

Electronic Signature Mark: /aes/

Date Signed: 20021223

I certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.

I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.

Attached Files:

fee-transmittal

IDS15300180002fee.xml

us-information-disclosure-statement

IDS15300180002ids.xml

Comments:

This IDS is being filed as two submissions on the same day. One submission is electronic and one submission is non-electronic. It is believed that only one fee under 37 C.F.R. 1.17(p) is required to cover both submissions. That fee is included with this electronic submission since this submission is expected to be processed first.

APP_ID=09839574

OFF 23 2012 STANGER PROPERTY OF STANGER PROPER

FEE TRANSMITTAL

RECEIVED

DEC 2 7 2002

TECH CENTER 1600/2900

Electronic Version 1.1.0 Stylesheet Version: 1.0

Patent fees are subject to annual revisions on or about October 1st of each year.

Large Entity

TOTAL FEES AUTHORIZED: \$ 180

BANK (CREDIT) CARD INFORMATION:

Credit Card Number:

1001

Expiration Date:

20040630

Authorized Name:

SKGF P.L.L.C.

Billing Address:

20005

ADDITIONAL FEES

Fee Description	Number	Quantity	Fee Code	Amount	Fee Paid
Submission Of Information Disclosure Stmt Fee		1	1806	\$ 180	\$ 180

Subtotal For Additional Fees: \$ 180



Electronic Filing System (EFS) Data **Electronic Patent Application Submission USPTO** Use Only

RECEIVED

DEC 2 7 2002

TECH CENTER 1600/2900

EFS ID:

21204

Application ID:

09839574

Compositions and Methods for in

vivo Delivery of Polynucleotide-Title of Invention:

Based Therapeutics Marston Manthorpe

First Named Inventor:

Domestic/Foreign Application:

Domestic Application

Filing Date:

2002-12-23

Effective Receipt Date:

Submission Type:

2002-12-23

Information Disclosure Statement

Filing Type:

null

Confirmation Number:

1437

Attorney Docket Number:

1530.0180002

Digital Certificate Holder:

cn=Ann E. Summerfield, ou=Registered Attorneys, ou=Patent and Trademark Office, ou=Department of Commerce, o=U.S.

Government, c=US

Certificate Message Digest:

tEHhefterab1rC0bl3WKnQ==

Total Fees Authorized:

\$180.0

Payment Category:

CC - Credit Card

Credit Card Number:

********1001

Expiration Date:

06302004

Card Holder Name:

SKGF P.L.L.C.

RAM User ID:

EFSPROD

RAM Accounting Date:

2002-12-23

RAM Sequence Number:

589040

RAM Payment Status:

RAM'success

Postal Code:

20005